Literature DB >> 26838210

Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.

Marut Laohaviroj1, Yaovalux Chamgramol, Chawalit Pairojkul, Jason Mulvenna, Banchob Sripa.   

Abstract

Cholangiocarcinoma (CCA) is generally a rare primary liver tumor of the bile duct with extremely poor clinical outcomes due to late diagnosis. Osteopontin (OPN) is the most abundant expressed gene in intrahepatic CCA and its involvement in tumor aggressiveness suggests it could be a useful prognostic biomarker. However, the prognostic significance of OPN expression in CCA is still controversial. We therefore immunohistochemically studied OPN expression in 354 resected CCAs and correlated the results with patient clinicopathological parameters. OPN expression was separately scored according to the percentage of cancer cells or degree of stromal tissue staining and classified as low (score 0-1) and high (score 2-3). OPN expression in CCA cells was found in 177 out of 354 patients (56.5%), whereas stroma was positive in 185 out of 354 patients (52.3%). Univariate analysis with several of the aforementioned parameters revealed that stromal but not cancer cell OPN expression was significantly associated with tumor size, tumor direct invasion into normal liver parenchyma, regional lymph node metastasis and higher staging. The combination of cancer cell and stromal OPN expression demonstrated a positive trend for linkage with lymph node metastasis. Multivariate analysis identified gender, the presence of lymphatic permeation and lymph node metastasis, but not OPN expression, as independent prognostic factors. This study confirms the presence of stromal OPN expression in tumor aggressiveness but not survival in CCA patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26838210      PMCID: PMC4955515          DOI: 10.7314/apjcp.2016.17.1.201

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  28 in total

Review 1.  Serum tumor markers in bile duct cancer--a review.

Authors:  M Grunnet; M Mau-Sørensen
Journal:  Biomarkers       Date:  2014-05-23       Impact factor: 2.658

2.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

3.  Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis.

Authors:  Qiang Huang; Lei Liu; Chen-Hai Liu; Feng Shao; Fang Xie; Chuan-Hai Zhang; San-Yuan Hu
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand.

Authors:  Sudarat Sriputtha; Narong Khuntikeo; Supannee Promthet; Supot Kamsa-Ard
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 5.  Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience.

Authors:  Narong Khuntikeo; Ake Pugkhem; Attapol Titapun; Vajarabhongsa Bhudhisawasdi
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-27       Impact factor: 7.027

6.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

Review 7.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

Review 8.  OPN -Revisited.

Authors:  Vijayanirmala Subraman; Muthukumar Thiyagarajan; N Malathi; Sharada T Rajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 9.  Cancer review: Cholangiocarcinoma.

Authors:  Yezaz Ahmed Ghouri; Idrees Mian; Boris Blechacz
Journal:  J Carcinog       Date:  2015-02-23

10.  Role of osteopontin in breast cancer patients.

Authors:  Antonio Macrì; Antonino Versaci; Giuseppe Lupo; Giuseppe Trimarchi; Chiara Tomasello; Saverio Loddo; Giuseppe Sfuncia; Rocco Caminiti; Diana Teti; Ciro Famulari
Journal:  Tumori       Date:  2009 Jan-Feb
View more
  4 in total

Review 1.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 2.  The Tumor Microenvironment in Cholangiocarcinoma Progression.

Authors:  Luca Fabris; Keisaku Sato; Gianfranco Alpini; Mario Strazzabosco
Journal:  Hepatology       Date:  2020-11-06       Impact factor: 17.298

Review 3.  Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases?

Authors:  Tomoya Iida; Kohei Wagatsuma; Daisuke Hirayama; Hiroshi Nakase
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

Review 4.  Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.

Authors:  Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.